The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 1,136 studies for Anemia, Sickle Cell across more than 10 countries. 240 are recruiting or about to start. 889 of them are mainly about Anemia, Sickle Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 4 narrower conditions too, such as Vaso-Occlusive Crises: 1,178 studies, 245 open.
ClinicalTrials.gov finds 1,214 studies for Anemia, Sickle Cell.How that becomes 1,136 here
This page counts the studies the registry files under Anemia, Sickle Cell, and those it files under no condition that list Anemia, Sickle Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count
1,214Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−5List Anemia, Sickle Cell as a condition, but the registry did not file them under itMost often written as “Sickle Cell Anemia in Children” (3) and “Healthy Volunteers Sickle Cell Disease, Thalassemia” (2). The registry filed them under other conditions only, most often Thalassemia (2) and Vitamin D Deficiency (1).
−31Match it another way27 name it in the title and 4 by a synonym or other text the search reads.
1,136The count on this page12 of them list Anemia, Sickle Cell in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 11 programs from 8 companies, 10 with this as their studies’ main aim; 5 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Agios Pharmaceuticals, CSL and Sanofi here →
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 4 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (6)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
7 Jan 2027 est.Pneumococcal 21-Valent Conjugate Vaccine· Sanofi · Phase 3main aimvs Pneumococcal 20-Valent Conjugate VaccineNCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — primary endpoint: Number of participants reporting immediate adverse events (AEs) · 100 enrolled
Jun 2027 est.Citrulline· Asklepion Pharmaceuticals, LLC · Phase 3named, not the main aimNCT06989567 A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis — primary endpoint: Change in pain score from baseline to discharge · 120 enrolled
23 Jul 2027 est.rilzabrutinib· Sanofi · Phase 3main aimNCT06975865 The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — primary endpoint: Annualized rate of clinical VOC · 192 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Anemia, Sickle Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
86studies finish main data collection within a year9 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger. 127 (72%) take children under 18. 6 (3%) are for women only and 0 (0%) for men only; 29 (16%) take healthy volunteers.
Across all 1,136 studies, recruiting or not: 56% stop at 75 or younger and 54% at 65; 65% take children; 2% are for women only and 1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Anemia, Sickle Cell studies take
Of 93 phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 46 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
36 mo18–65 · 58 studies
24 mo9–41 · 28 studies
—
Phase 1/2
82 mo44–222 · 37 studies
—
—
Phase 2
46 mo24–73 · 93 studies
28 mo16–41 · 34 studies
54 mo42–117 · 59 studies
Phase 3
48 mo36–61 · 35 studies
—
—
Phase 4
24 mo13–41 · 20 studies
—
—
Interventional, no phase
28 mo15–49 · 173 studies
—
28 mo17–54 · 165 studies
Observational
49 mo24–109 · 139 studies
—
48 mo23–109 · 130 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.